Status:
COMPLETED
Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
COVID-19 Virus Disease
Cardiac Complication
Eligibility:
All Genders
18-79 years
Brief Summary
Coronavirus Disease 2019 (COVID-19) is an infection caused by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), which affects multiple organ system particularly the lung and heart. Indeed, S...
Eligibility Criteria
Inclusion
- Cardiac involvement confirmed : increase troponin level \> 50pg/ml or left ventricular dysfunction assessed by echocardiography during hospitalization for confirmed COVID-19 infection
- Absence of severe renal failure (CKD EPI \> 30ml/min/1.73m²)
- Cardic imaging (MRI and TTE) performed during 4 months from COVID-19 infection
Exclusion
- Cardiovascular history (ischemic or valvular disease, dilated cardiomyopathy, cardiac surgery...)
- Vulnerable patient (pregnancy, adult under legal protection)
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04753762
Start Date
March 1 2020
End Date
February 1 2022
Last Update
May 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laura FILIPPETTI
Vandœuvre-lès-Nancy, France, 54500